Available Technologies

Details

Project TitleCaptin: a Calcineurin Peptide Inhibitor
Track Code2017-155
Short Description
Abstract
 
Tagsimmunosuppressant, low toxicity, Calcineurin, cyclosporine
 
Posted DateAug 4, 2017 6:27 PM

Market Opportunity

Immunosuppressant drugs have a variety of uses, from preventing the body’s rejection of transplanted organs, to treatment of autoimmune diseases. Calcineurin is a high profile target of many immunosuppressant drugs, such as Cyclosporine.  While effective, these drugs also come with many toxic side effects causing dizziness, headaches and even hypertension. Therefore there is a need for a safer, less toxic, calcineurin inhibitor.

USC Solution

USC researchers have developed a peptide inhibitor of calcineuirn: Captin (calcineurin peptide inhibitor). Captin has shown excellent binding affinity for calcineurin.  Additionally Captin has been effective at inhibiting phosphatase activity of calcineuirn without exhibiting any toxicity towards T lymphocyte cells, making captin a good candidate for future use in immunosuppressive therapy.

Value Proposition

  • High binding affinity
  • Inhibits Calcineurin
  • Low toxicity

Applications

  • Immunosuppressant drug candidate

Stage of Development

  • Validated binding and inhibition in vitro
  • Available for exclusive license

Intellectual Property

Status:

Patent Pending 62/491,207


Key Publication:

Pending

Contact Information

Patrick Maloney, Licensing Associate

USC Stevens Center for Innovation

(213) 821-6064

pmaloney@usc.edu

Files

File Name Description
NCD 2017-155 - Captin (Peptide Inhibitor of Calcineurin).pdf None Download